Antiviral Agents against Omicron Subvariant BA.4.6 In Vitro

To the Editor: Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside the receptor-binding motif (RBM), depends on the expression level of the SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [ACE2]), whereas...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 5; p. e12
Main Authors Walker, Jill, Schnell, Gretja, Kerr, William, Uraki, Ryuta, Imai, Masaki, Kawaoka, Yoshihiro
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 02.02.2023
Subjects
ACE2
Angiotensin
Angiotensin-converting enzyme 2
Antiviral agents
Antiviral Agents - therapeutic use
Conflicts of interest
Humans
Monoclonal antibodies
Peptidyl-dipeptidase A
Severe acute respiratory syndrome coronavirus 2
United States > US
San Francisco California
Online AccessGet full text

Cover

More Information
Summary:To the Editor: Studies have shown that the neutralization activity of antibodies such as S309 (the precursor of sotrovimab) or sotrovimab, which bind outside the receptor-binding motif (RBM), depends on the expression level of the SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [ACE2]), whereas the activity of RBM-targeting monoclonal antibodies is not considerably affected by ACE2 receptor expression. 1,2 Three recent letters in the Journal from a group at the University of Tokyo (Aug. 4 and Dec. 1, 2022, and Jan. 5, 2023, issues) 3-5 reported substantial loss of in vitro neutralization activity with S309 against recent B.1.1.529 (omicron) variants. This group cites the . . .
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Commentary-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2216611